For a patient on amikacin for an Acinetobacter baumannii urinary tract infection who initially improved but now has a relapse with a high risk of multidrug-resistant organism, what additional antimicrobial agent should be added?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Add Colistin or Sulbactam to Amikacin for MDR Acinetobacter baumannii UTI Relapse

For this patient with suspected MDR Acinetobacter baumannii urinary tract infection failing amikacin monotherapy, add colistin (polymyxin E) with a loading dose of 5 mg CBA/kg IV, then maintenance dosing of 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h. Alternatively, if susceptibility testing shows sulbactam MIC ≤4 mg/L, add sulbactam 9-12 g/day in 3-4 divided doses as a safer option 1.

Rationale for Combination Therapy

The clinical scenario of initial improvement followed by relapse strongly suggests:

  • Emergence of resistance during amikacin monotherapy
  • Inadequate source control or persistent infection
  • High probability of carbapenem-resistant organism given the MDR risk factors

Amikacin monotherapy is explicitly not recommended for severe MDR Acinetobacter infections outside of urinary tract infections 1. Even for UTIs, the 2022 guidelines note aminoglycosides as monotherapy are "only indicated for urinary tract infections" in the context of carbapenem-resistant organisms 2. Your patient's relapse indicates monotherapy has failed.

Primary Recommendation: Add Colistin

Colistin (polymyxin E) is the most evidence-based addition for suspected carbapenem-resistant A. baumannii with high MDR risk 1:

  • Loading dose is critical: 6-9 million IU (equivalent to 5 mg CBA/kg) to achieve therapeutic levels rapidly 1
  • Maintenance dosing: 4.5 million IU q12h for patients with CrCl >50 mL/min, adjusted by formula: 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h 1
  • Rationale: Colistin is suggested as empirical treatment "in patients with severe infections and high probability of CR A. baumannii, such as during outbreaks or in patients colonized with this pathogen" 1

Colistin Dosing Specifics

The 2015 ICU task force emphasizes that suboptimal plasma concentrations are common without loading doses, with therapeutic levels taking 2-3 days to achieve with maintenance dosing alone 1. For urinary tract infections specifically, colistin achieves high urinary concentrations and remains active.

Alternative: Add Sulbactam (If Susceptible)

If susceptibility testing shows sulbactam MIC ≤4 mg/L, sulbactam may be preferable to colistin based on superior safety profile 1:

  • Dose: 9-12 g/day divided into 3-4 doses (3 g q6-8h)
  • Infusion: 4-hour infusion recommended for optimal pharmacodynamics 1
  • Evidence: Multiple studies show sulbactam comparable or superior to colistin for MDR A. baumannii with significantly lower nephrotoxicity (15.3% vs 33%) 1

The 2015 guideline states: "In strains susceptible to colistin and demonstrating a low MIC for sulbactam (≤4 mg/L), the use of sulbactam may be preferable in the directed therapy based on its better safety profile" 1.

Why Not Other Options?

Tigecycline

Not recommended for urinary tract infections - tigecycline achieves poor urinary concentrations and is explicitly noted to have "limited solubility in urine" and "should be avoided for urinary pathogens" 3. The 2022 guidelines do not list tigecycline for complicated UTIs caused by carbapenem-resistant organisms 2.

Carbapenem Addition

While high-dose meropenem (2 g q8h extended infusion) is mentioned in combination regimens 2, this is primarily for carbapenem-resistant Enterobacterales, not A. baumannii. The 2015 guideline explicitly states "carbapenems should not be used, at least in monotherapy, for severe infections in areas with a high rate of resistance" 1.

Newer Beta-Lactam Combinations

Ceftazidime-avibactam, meropenem-vaborbactam, and ceftolozane-tazobactam have limited activity against A. baumannii and are primarily indicated for carbapenem-resistant Enterobacterales and Pseudomonas 2. The 2024 guideline mentions sulbactam-durlobactam for CRAB but notes it is "not approved in Europe" 4, 5.

Critical Action Steps

  1. Obtain repeat urine culture immediately before adding therapy
  2. Request susceptibility testing including colistin, sulbactam, tigecycline, and carbapenems
  3. Assess renal function carefully - both colistin and amikacin are nephrotoxic
  4. Ensure adequate hydration to minimize aminoglycoside nephrotoxicity 6
  5. Consider infectious disease consultation for MDR organism management

Common Pitfalls to Avoid

  • Do not delay loading dose of colistin - maintenance dosing alone results in 2-3 days of subtherapeutic levels 1
  • Do not use tigecycline for UTI - inadequate urinary concentrations 3
  • Do not continue amikacin alone - monotherapy failure indicates need for combination 1
  • Monitor for nephrotoxicity - combination of amikacin + colistin increases risk; consider switching to sulbactam if available and susceptible 1
  • Avoid colistin dose errors - multiple dosing conventions exist (CMS vs CBA vs IU); use standardized formulas 1

Duration and Monitoring

  • Treatment duration: 5-7 days for complicated UTI, individualized based on clinical response 2
  • Monitor: Daily renal function, clinical improvement within 48-72 hours
  • De-escalate based on culture results and susceptibility testing
  • Consider source control: Ensure no urinary obstruction, foreign bodies, or anatomic abnormalities

The combination approach is supported by metabolomic studies showing that polymyxin-amikacin-sulbactam triple therapy produces greater metabolic disruption in MDR A. baumannii than double combinations 7, though clinical translation of this finding requires sulbactam susceptibility.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.